• Home
  • All News Articles
  • TraCS Director Dr. John Buse receives 2019 Outstanding Achievement in Clinical Diabetes Research Award

TraCS Director Dr. John Buse receives 2019 Outstanding Achievement in Clinical Diabetes Research Award

John Buse, MD, PhD

John Buse, MD, PhD, the Verne S. Caviness Distinguished Professor of Medicine, and Elizabeth Davis-Mayer, PhD, the Cary C. Boshamer Distinguished Professor of Nutrition and Medicine, will be honored at the annual American Diabetes Association Scientific Sessions for their clinical research and epidemiological work.

John B. Buse, MD, PhD, is the recipient of the 2019 Outstanding Achievement in Clinical Diabetes Research Award given by the American Diabetes Association. This award recognizes exceptional contributions in patient-oriented clinical outcomes research that have had a significant impact on diabetes prevention and treatment.

Elizabeth J. Mayer-Davis, PhD

Elizabeth J. Mayer-Davis, PhD, is the recipient of the 2019 Kelly West Award for Outstanding Achievement in Epidemiology. Supported by an unrestricted educational grant from Merck , this award recognizes significant contributions to the field of diabetes epidemiology. Mayer-Davis will deliver the Kelly West Award Lecture on Sunday, June 9.

Buse is the Verne S. Caviness Distinguished Professor, chief of the division of endocrinology in the department of medicine, director of the UNC Diabetes Care Center, Director of the NC Translational and Clinical Sciences (NC TraCS) Institute and Executive Associate Dean for Clinical Research at the University of North Carolina. Embodying excellence and innovative leadership, Buse has led or participated in more than 200 clinical studies and dozens of epidemiologic analyses and translational projects.

His breadth of investigation ranges from early stage clinical characterization of new molecular entities to seminal trials, including critical drug safety outcomes studies. He is renowned for co-chairing the ACCORD trial, which demonstrated a lack of benefit of more intensive goals for glycemia, blood pressure and lipids, and for chairing the LEADER trial, which was the first demonstration of the broad effect of the GLP-1 receptor agonist liraglutide to reduce cardiovascular events and mortality in patients with type 2 diabetes at high cardiovascular risk.

Buse has been listed since 2015 among Thompson Reuters "Highly Cited Researchers" recognizing the top 1 percent of global investigators and is widely sought after as a lecturer, consultant, collaborator and clinical trial investigator.

Mayer-Davis is the Cary C. Boshamer Distinguished Professor of Nutrition and Medicine, and chair of the department of nutrition at the UNC Gillings School of Global Public Health and the UNC School of Medicine. With research focused on the epidemiology of diabetes in youth and young adults, her body of work is described in more than 300 peer reviewed papers and book chapters. Mayer-Davis has conducted trials in type 2 diabetes prevention and type 1 diabetes treatment. She has also performed observational studies of diabetes complications and the role of nutrition. Much of her work has focused on translating research to understand clinical and public health implications.

Both will be honored at the 79th ADA Scientific Sessions.


Originally published at UNC Health Care Newsroom.

View news related to policies and regulations

Have news or an announcement to share? Contact Michelle Maclay at michelle_maclay@med.unc.edu

Get NC TraCS events and news delivered to your inbox! Subscribe to our weekly email blast

NC TraCS Institute logo vertical

In partnership with:

Contact Us


Brinkhous-Bullitt, 2nd floor
160 N. Medical Drive
Chapel Hill, NC 27599

919.966.6022
This email address is being protected from spambots. You need JavaScript enabled to view it.

Social


Cite Us


CitE and SUBMit CTSA Grant number - UM1TR004406

© 2008-2024 The North Carolina Translational and Clinical Sciences (NC TraCS) Institute at The University of North Carolina at Chapel Hill
The content of this website is solely the responsibility of the University of North Carolina at Chapel Hill and does not necessarily represent the official views of the NIH   accessibility | contact